NASDAQ: HROWHarrow Inc Stock
$30.31-0.85 (-2.73%)
Updated Jun 13, 2025
HROW Price
$30.31
Fair Value Price
N/A
Market Cap
$1.11B
52 Week Low
$16.87
52 Week High
$59.23
P/E
-49.69x
P/B
19.7x
P/S
4.48x
PEG
N/A
Dividend Yield
N/A
Revenue
$212.86M
Earnings
-$21.70M
Gross Margin
74.5%
Operating Margin
1.12%
Profit Margin
-10.2%
Debt to Equity
5.46
Operating Cash Flow
$2M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HROW Overview
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HROW's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
HROW
Ranked#47 of 59
Ranked#47 of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.93 | A | |
| $5.24 | A | |
| $6.88 | A |
Be the first to know about important HROW news, forecast changes, insider trades & much more!
HROW News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HROW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HROW is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HROW is poor value based on its book value relative to its share price (19.7x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.26x)
P/B vs Industry Valuation
HROW is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HROW due diligence checks available for Premium users.
Valuation
HROW price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-49.69x
Industry
-23.1x
Market
31.36x
HROW price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
19.7x
Industry
2.26x
HROW is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HROW's financial health
Profit margin
Revenue
$47.8M
Net Income
-$17.8M
Profit Margin
-37.2%
HROW's Earnings (EBIT) of $2.38M... subscribe to Premium to read more.
Interest Coverage Financials
HROW's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$364.2M
Liabilities
$308.1M
Debt to equity
5.46
HROW's short-term liabilities ($186.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HROW's short-term assets ($169.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HROW's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HROW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$19.7M
Investing
-$212.0k
Financing
$23.0k
HROW's operating cash flow ($2.09M)... subscribe to Premium to read more.
Debt Coverage Financials
HROW vs Pharmaceutical Stocks
Harrow Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.